Efforts are underway to revise how multiple sclerosis (MS) is classified, moving from traditional symptom-based categories toward a more biologically based framework. Current descriptors like relapsing-remitting or progressive MS don’t fully capture the complexity of the disease or the differences in how it presents and progresses in individuals. By incorporating biomarkers and other measurable biological data, researchers hope to better understand what drives MS and offer more personalized treatment options. This shift could also lead to more targeted clinical trials and faster development of effective therapies, though the transition will require careful planning and collaboration across the MS community.
